Haploidentical Hematopoietic Stem Cell Transplantation Drives Time-dependent premature T Cell Senescence: Recipient
Lin Sun1, Yichen Zhang2, Hong Zhang3
1Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Hematology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Abstract:
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) cures hematological malignancies but severely impairs long-term immune reconstitution by inducing T cell senescence. Previous studies have linked anti-tumor therapy to immune aging; however, it remains unclear whether haploidentical HSCT (haplo-HSCT) independently drives progressive premature T cell senescence beyond pre-transplant chemotherapy, and how the recipient microenvironment shapes donor T cell aging patterns. This study aimed to determine the independent effect of haplo-HSCT on time-dependent T cell senescence and to elucidate the bidirectional regulatory role of recipient age-associated microenvironments on phenotypic and molecular aging signatures of donor-derived T cells. A total of 34 subjects were enrolled, including 24 haplo-HSCT recipients stratified by post-transplant duration (<12 months, n = 12; ≥12 months, n = 12) and 10 patients receiving chemotherapy alone. Eighteen age-reciprocal donor-recipient pairs were analyzed. Multiparameter flow cytometry, multiplex cytokine assay, SASP PCR array, epigenetic clock profiling, and telomere length measurement were performed to comprehensively characterize T cell senescence features. Haplo-HSCT induced robust, time-dependent senescence in both CD4⁺ and CD8⁺ T cells, accompanied by substantial T cell subset remodeling. This included a reduced CD4/CD8 ratio, contracted naive and central memory T cell compartments, and expansion of senescence-prone terminal effector memory T cells, which was particularly pronounced in the CD8⁺ compartment. Terminal senescent CD27⁻CD28⁻CD57⁺ T cells (both CD4⁺ and CD8⁺) from long-term recipients exhibited significantly upregulated canonical senescence molecules p16INK4a and γH2AX, providing solid molecular evidence for transplant-associated T cell senescence. In contrast, chemotherapy alone failed to induce comparable terminal T cell senescence phenotypes. Haplo-HSCT further established persistent peripheral inflammatory imbalance and remodeled the prosenescent SASP transcriptional profile of circulating T cells. Notably, recipient age exerted bidirectional modulation of donor T cell epigenetic aging, telomere homeostasis, and SASP remodeling. Haplo-HSCT serves as an independent, time-dependent driver of premature donor T cell senescence, distinct from chemotherapy-induced immune alteration. The recipient age-related microenvironment is a critical regulator of donor T cell epigenetic aging, telomere maintenance and SASP reprogramming. This study systematically delineates multi-layered signatures of post-transplant T cell senescence and provides a theoretical foundation for developing age-adapted strategies to improve long-term immune reconstitution after haplo-HSCT.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Replicative Cell Senescence
iPS Cell Differentiation
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...


